Catalyst Pharmaceuticals appoints Tamar Thompson to Board; Board expands to 8 members

CATALYST PHARMACEUTICALS, INC.

Tamar Thompson appointed to the Board effective May 25, 2023; Board size increased from 7 to 8.
Thompson is VP, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Diseases.
She brings over 20 years of experience in rare diseases, health policy, and government affairs.
Previously served as Executive Director, State Govt Affairs & Federal Policy at Bristol-Myers Squibb.
No family relationships or transactions with Catalyst exceeding $120,000 reported.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tamar Thompson

Director

CPRX · CATALYST PHARMACEUTICALS, INC.

Effective: 2023-05-25
Filed: May 30, 2023, 7:59 PM ET

has appointed Tamar Thompson to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tamar Thompson was appointed as Director at CATALYST PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

has appointed Tamar Thompson to the Board.

View on SEC.gov

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-156642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.